© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 11, 918-923,
June 7, 2000
© 2000 Oxford University Press
Somatic Mutation Screening: Identification of Individuals Harboring K-ras Mutations With the Use of Plasma DNA
Affiliations of authors: M. S. Kopreski, OncoMEDx, Inc., Columbia, MD; F. A. Benko, D. J. Borys (Department of Pathology), A. Khan, T. J. McGarrity (Department of Medicine), Penn State Geisinger–Hershey Medical Center, PA; C. D. Gocke, Department of Pathology, Penn State Geisinger–Hershey Medical Center and OncoMEDx, Inc.
Correspondence to: Christopher D. Gocke, M.D., Department of Pathology, Penn State Geisinger–Hershey Medical Center, P.O. Box 850, Hershey, PA 17033 (e-mail: cgocke{at}psghs.edu).
Background: Many cancers are attributed to somatic mutation of DNA. We investigated whether it is feasible to detect cancer-associated somatic mutations in patients with neoplasms by using plasma DNA. Methods: Plasma samples were prospectively collected from 240 patients undergoing colonoscopy. Colorectal biopsies were performed as clinically indicated in 135 patients, and risk factor information was available from 232 patients. DNA was extracted from plasma and colorectal tissue and was amplified by use of a polymerase chain reaction method that enriches for mutations in codon 12 of the K-ras oncogene. Molecular, histologic, and clinical data were compared by use of two-sided Fisher's exact test. Results: Mutations in the K-ras gene detected in the plasma of 64 (28%) of 232 patients were statistically significantly associated with colorectal cancer risk factors (P = .0002). Of those patients having tissue available for comparison (n = 135), mutations in the K-ras gene were found in the tissues of 35 patients, and 29 (83%) of these 35 showed mutations in plasma samples. In contrast, the plasma assay was negative in 93 of the 100 patients whose tissue K-ras was wild-type. Among patients without biopsies (n = 105), 28 had mutated K-ras in their plasma DNA, despite the absence of remarkable colonoscopy findings; 24 of these 28 patients had risk factors for colorectal cancer. Overall, 25 (39%) of 64 patients showing mutations in plasma DNA had colorectal neoplasms with K-ras mutations compared with five (3%) of 176 patients without K-ras mutations in plasma DNA. Conclusion: Plasma DNA assays for the detection of mutations in K-ras codon 12 may provide a feasible method to screen populations for somatic mutations frequently found in neoplasms. The clinical utility of using this test in screening populations requires further study.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Amicarelli, E. Shehi, G. M. Makrigiorgos, and D. Adlerstein FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations Nucleic Acids Res., October 11, 2007; (2007) gkm809v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hundt, U. Haug, and H. Brenner Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1935 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Haug, T. Hillebrand, P. Bendzko, M. Low, D. Rothenbacher, C. Stegmaier, and H. Brenner Mutant-Enriched PCR and Allele-Specific Hybridization Reaction to Detect K-ras Mutations in Stool DNA: High Prevalence in a Large Sample of Older Adults Clin. Chem., April 1, 2007; 53(4): 787 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Flamini, L. Mercatali, O. Nanni, D. Calistri, R. Nunziatini, W. Zoli, P. Rosetti, N. Gardini, A. Lattuneddu, G. M. Verdecchia, et al. Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal Cancer Clin. Cancer Res., December 1, 2006; 12(23): 6985 - 6988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Garcia-Olmo, L. Gutierrez-Gonzalez, J. Samos, M. G. Picazo, M. Atienzar, and D. Garcia-Olmo Surgery and Hematogenous Dissemination: Comparison Between the Detection of Circulating Tumor Cells and of Tumor DNA in Plasma Before and After Tumor Resection in Rats Ann. Surg. Oncol., August 1, 2006; 13(8): 1136 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gormally, P. Vineis, G. Matullo, F. Veglia, E. Caboux, E. Le Roux, M. Peluso, S. Garte, S. Guarrera, A. Munnia, et al. TP53 and KRAS2 Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study. Cancer Res., July 1, 2006; 66(13): 6871 - 6876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Trombino, M. Neri, R. Puntoni, C. Angelini, M. Loprevite, A. Cesario, P. Granone, A. Imperatori, L. Dominioni, A. Ardizzoni, et al. Mutations in K-ras Codon 12 Detected in Plasma DNA Are Not an Indicator of Disease in Patients with Non-Small Cell Lung Cancer Clin. Chem., July 1, 2005; 51(7): 1313 - 1314. [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Su, M. Wang, D. E. Brenner, A. Ng, H. Melkonyan, S. Umansky, S. Syngal, and T. M. Block Human Urine Contains Small, 150 to 250 Nucleotide-Sized, Soluble DNA Derived from the Circulation and May Be Useful in the Detection of Colorectal Cancer J. Mol. Diagn., May 1, 2004; 6(2): 101 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. C. Wong, S. F. E. Lo, M. T. Cheung, K. O. E. Ng, C. W. Tse, B. S. P. Lai, K. C. Lee, and Y. M. D. Lo Quantification of Plasma {beta}-Catenin mRNA in Colorectal Cancer and Adenoma Patients Clin. Cancer Res., March 1, 2004; 10(5): 1613 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B M Ryan, F Lefort, R McManus, J Daly, P W N Keeling, D G Weir, and D Kelleher A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up Mol. Pathol., June 1, 2003; 56(3): 172 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B M Ryan, F Lefort, R McManus, J Daly, P W N Keeling, D G Weir, and D Kelleher A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up Gut, January 1, 2003; 52(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bearzatto, D. Conte, M. Frattini, N. Zaffaroni, F. Andriani, D. Balestra, L. Tavecchio, M. G. Daidone, and G. Sozzi p16INK4A Hypermethylation Detected by Fluorescent Methylation-specific PCR in Plasmas from Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2002; 8(12): 3782 - 3787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Johnson and Y.M. D. Lo Plasma Nucleic Acids in the Diagnosis and Management of Malignant Disease Clin. Chem., August 1, 2002; 48(8): 1186 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M Silva, R Rodriguez, J M Garcia, C Munoz, J Silva, G Dominguez, M Provencio, P Espana, and F Bonilla Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells Gut, April 1, 2002; 50(4): 530 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dominguez, J. Carballido, J. Silva, J. M. Silva, J. M. Garcia, J. Menendez, M. Provencio, P. Espana, and F. Bonilla p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients Clin. Cancer Res., April 1, 2002; 8(4): 980 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Taback, Y. Fujiwara, H.-J. Wang, L. J. Foshag, D. L. Morton, and D. S. B. Hoon Prognostic Significance of Circulating Microsatellite Markers in the Plasma of Melanoma Patients Cancer Res., August 1, 2001; 61(15): 5723 - 5726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sozzi, D. Conte, L. Mariani, S. Lo Vullo, L. Roz, C. Lombardo, M. A. Pierotti, and L. Tavecchio Analysis of Circulating Tumor DNA in Plasma at Diagnosis and during Follow-Up of Lung Cancer Patients Cancer Res., June 1, 2001; 61(12): 4675 - 4678. [Abstract] [Full Text] [PDF]
|
|